Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,079)

Items 501–600 of 1,079

1. The EMT regulator slug and lung carcinogenesis
   Jin-Yuan Shih, Pan‐Chyr Yang · 2011 · Carcinogenesis
2. Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
   Toru Mukohara, Jeffrey A. Engelman, Nasser H. Hanna, Beow Yong Yeap, Susumu S. Kobayashi, Neal Ian Lindeman, Balázs Halmos, Joseph Pearlberg, Zenta Tsuchihashi, Lewis C. Cantley et al. · 2005 · JNCI Journal of the National Cancer Institute
3. Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
   Teh‐Ying Chou, Chao‐Hua Chiu, Ling‐Hui Li, Chun-Yen Hsiao, Chin‐Yuan Tzen, Kuo-Ting Chang, Yuh‐Min Chen, Reury-Perng Perng, Shih‐Feng Tsai, Chun‐Ming Tsai · 2005 · Clinical Cancer Research
4. Quantitative Detection of <i>EGFR</i> Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
   Taniguchi, Kazuya, Uchida, Junji, Nishino, Kazumi, Kumagai, Toru, Okuyama, Takako, Okami, Jiro, Higashiyama, Masahiko, Kodama, Ken, Imamura, Fumio, Kato, Kikuya · 2011 · Clinical Cancer Research
5. Circulating tumor cells: a window into cancer biology and metastasis
   Shyamala Maheswaran, Daniel A. Haber · 2010 · Current Opinion in Genetics & Development
6. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer
   Emily H. Castellanos, Emily Feld, Leora Horn · 2016 · Journal of Thoracic Oncology
7. Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation
   Porta, R., Sánchez-Torres, J.M., Paz-Ares, L., Massutí, B., Reguart, N., Mayo, C., Lianes, P., Queralt, C., Guillem, V., Salinas, P. et al. · 2011 · European Respiratory Journal
8. Somatic Mutations ofEGFRin Colorectal Cancers and Glioblastomas
   Thomas D. Barber, Bert Vogelstein, Kenneth W. Kinzler, Victor E. Velculescu · 2004 · New England Journal of Medicine
9. EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
   Maria Paola Martelli, Gabriella Sozzi, Luís Hernández, Valentina Pettirossi, Alba Navarro, Davide Conte, Patrizia Gasparini, Federica Perrone, Piergiorgio Modena, Ugo Pastorino et al. · 2009 · American Journal Of Pathology
10. Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy
    Deepali Sachdev, Douglas Yee · 2008 · AACR Education book
11. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
    Mi Ran Kang, Min Sung Kim, Ji Eun Oh, Yoo Ri Kim, Sang Yong Song, Seong Il Seo, Ji Youl Lee, Nam Jin Yoo, Sug Hyung Lee · 2009 · International Journal of Cancer
12. Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study
    Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, Heinrich Röder, Robert J. Gray, Kazuo Kasahara, Makoto Nishio, Julie Renee Brahmer, Anna Spreafico, Vienna Ludovini et al. · 2007 · JNCI Journal of the National Cancer Institute
13. Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts
    David Neil Hayes, Stefano Monti, Giovanni Parmigiani, C. Blake Gilks, Katsuhiko Naoki, Arindam Bhattacharjee, Mark A. Socinski, Charles M. Perou, Matthew M. Meyerson · 2006 · Journal of Clinical Oncology
14. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
    Eskil Eskilsson, Gro Vatne Røsland, Gergely Morten Solecki, Qianghu Wang, Patrick N. Harter, Grazia Graziani, Roel G.W. Verhaak, Frank Winkler, Rolf Bjerkvig, Hrvoje Miletić · 2017 · Neuro-Oncology
15. A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
    Chang, Kai-Hsiung, Li, Rui, Kuri, Barbara, Lotan, Yair, Roehrborn, Claus G., Liu, Jiayan, Vessella, Robert, Nelson, Peter S., Kapur, Payal, Guo, Xiaofeng et al. · 2013 · Cell
16. High frequency of BRAF V600E mutations in ameloblastoma
    Kari J. Kurppa, Javier Catón, Peter R. Morgan, Ari P. Ristimaki, B. Ruhin, Jari K. Kellokoski, Klaus Elenius, Kristiina Heikinheimo · 2013 · The Journal of Pathology
17. Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
    Amit Kumar, Edward T. Petri, Balázs Halmos, Titus J. Boggon · 2008 · Journal of Clinical Oncology
18. Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices
    Nathan A. Pennell, Maria E. Arcila, David R. Gandara, Howard West · 2019 · American Society of Clinical Oncology Educational Book
19. Clinical trial design in the era of precision medicine
    Elena Fountzilas, Apostolia Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock · 2022 · Genome Medicine
20. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
    Michael R. Burgess, Brian J. Skaggs, Neil P. Shah, Francis Y. Lee, Charles L. Sawyers · 2005 · Proceedings of the National Academy of Sciences
21. Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
    Bryan C. Fuchs, Tsutomu Fujii, Jon D. Dorfman, Jonathan M. Goodwin, Andrew Xiuxuan Zhu, Michael D. Lanuti, Kenneth K. Tanabe · 2008 · Cancer Research
22. The Evolving Landscape of Brain Metastasis
    Manuel Valiente, Manmeet Singh Ahluwalia, Adrienne Ann Boire, Priscilla Kaliopi Brastianos, Sarah B. Goldberg, Eudocia Q. Lee, Émilie Le Rhun, Matthias Preusser, Frank Winkler, Riccardo Soffietti · 2018 · Trends in cancer
23. Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
    Jura, Natalia, Zhang, Xuewu, Endres, Nicholas F., Seeliger, Markus A., Schindler, Thomas, Kuriyan, John · 2011 · Molecular Cell
24. Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects
    Laura P. Stabile, Jennifer S. Lyker, Christopher T. Gubish, Weiping Zhang, Jennifer Rubin Grandis, Jill M. Siegfried · 2005 · Cancer Research
25. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
    Michaela Jane Higgins, Danijela Jelovac, Evan Barnathan, Brian Blair, Shannon A. Slater, Penny Powers, Jane Zorzi, Stacie C. Jeter, George R. Oliver, John H. Fetting et al. · 2012 · Clinical Cancer Research
26. Visceral obesity, metabolic syndrome, insulin resistance and cancer
    Suzanne L. Doyle, Claire L. Donohoe, Joanne Lysaght, John Vincent Reynolds · 2011 · Proceedings of The Nutrition Society
27. Recent Advances in the Treatment of Malignant Astrocytoma
    David A. Reardon, Jeremy N. Rich, Henry S. Friedman, Darell D. Bigner · 2006 · Journal of Clinical Oncology
28. Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
    David Michael Jackman, Beow Yong Yeap, Neal Ian Lindeman, Panos Fidias, Michael S. Rabin, Jennifer S. Temel, Arthur T. Skarin, Matthew M. Meyerson, Alison Holmes Tisch, Ana M. Borras et al. · 2007 · Journal of Clinical Oncology
29. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
    Yang Yang, Shuo Li, Yujiao Wang, Yi Zhao, Qiu Li · 2022 · Signal Transduction and Targeted Therapy
30. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
    Erin Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming‐Sound Tsao · 2015 · Europe PMC (PubMed Central)
31. Flying under the radar: the new wave of BCR–ABL inhibitors
    Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jörge E. Cortes · 2007 · Nature Reviews Drug Discovery
32. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
    Sun, Chong, Hobor, Sebastijan, Bertotti, Andrea, Zecchin, Davide, Huang, Sidong, Galimi, Francesco, Cottino, Francesca, Prahallad, Anirudh, Grernrum, Wipawadee, Tzani, Anna et al. · 2014 · Cell Reports
33. Mechanisms for oncogenic activation of the epidermal growth factor receptor
    Roza Zandi, Alice Bjerregaard Larsen, Peter Andersen, Marie‐Thérése Stockhausen, Hans Skovgaard Poulsen · 2007 · Cellular Signalling
34. Integration of EGFR inhibitors with radiochemotherapy
    Mukesh Kumar Nyati, Meredith Ann Morgan, Felix Yi-Chung Feng, Theodore Steven Lawrence · 2006 · Nature reviews. Cancer
35. A comprehensive review of protein kinase inhibitors for cancer therapy
    Radhamani Kannaiyan, Daruka Mahadevan · 2018 · Expert Review of Anticancer Therapy
36. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
    Pasi Antero Janne, Nathanael S. Gray, Jeff Settleman · 2009 · Nature Reviews Drug Discovery
37. Mouse models for human lung cancer
    Ralph Leo Johan Meuwissen, Anton J. M. Berns · 2005 · Genes & Development
38. <i>EGFR</i> mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
    Ellison, Gillian, Zhu, Guanshan, Moulis, Alexandros, Dearden, Simon, Speake, Georgina, McCormack, Rose · 2013 · Journal of Clinical Pathology
39. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
    Heae Surng Park, Min Hye Jang, Eun Joo Kim, Hyun Jeong Kim, Hee Jin Lee, Yu Jung Kim, Jee Hyun Kim, Eunyoung Kang, Sung‐Won Kim, In Ah Kim et al. · 2014 · Modern Pathology
40. Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Wang, Wei, Li, Qi, Yamada, Tadaaki, Matsumoto, Kunio, Matsumoto, Isao, Oda, Makoto, Watanabe, Go, Kayano, Yoshiyuki, Nishioka, Yasuhiko, Sone, Saburo et al. · 2009 · Clinical Cancer Research
41. Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases
    Albrecht Moritz, Li Yu, Ailan Guo, Judit Villén, Yi Wang, Joan MacNeill, Jon M. Kornhauser, Kam M. Sprott, Jing Zhou, Anthony P. Possemato et al. · 2010 · Science Signaling
42. Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
    Sandra P. D’Angelo, Maria Catherine Pietanza, Melissa Lynne Johnson, Gregory J. Riely, Vincent A. Miller, Camelia S. Sima, Maureen Frances Zakowski, Valerie W. Rusch, Marc Ladanyi, Mark G. Kris · 2011 · Journal of Clinical Oncology
43. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
    Camilla Krakstad, Martha Chekenya · 2010 · Molecular Cancer
44. Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
    David A. Eberhard, Giuseppe Giaccone, Bruce Evan Johnson · 2008 · Journal of Clinical Oncology
45. Translating insights from the cancer genome into clinical practice
    Lynda Chin, Joe W. Gray · 2008 · Nature
46. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
    Yi-Long Lung Cancer Wu, Jin Soo Lee, Sumitra Thongprasert, Chong‐Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu et al. · 2013 · The Lancet Oncology
47. Genomics and the Continuum of Cancer Care
    Ultan McDermott, James R. Downing, Michael R. Stratton · 2011 · New England Journal of Medicine
48. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
    Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, Christos Vaklavas, Nisha Anjali Mohindra, Aparna Kalyan, Maria Matsangou, Ricardo Lima Barros Costa, Benedito A. Carneiro, Victoria Meucci Villaflor et al. · 2016 · Oncotarget
49. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
    Mitsuhiko Hanawa, Shioto Suzuki, Yoh Dobashi, Tetsu Yamane, Koji Kono, Nobuyuki Enomoto, Akishi Ooi · 2005 · International Journal of Cancer
50. A Translational View of the Molecular Pathogenesis of Lung Cancer
    Mitsuo Sato, David S. Shames, Adi F. Gazdar, John Dorrance Minna · 2007 · Journal of Thoracic Oncology
51. Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
    William M. Lin, Alissa C. Baker, Rameen Beroukhim, Wendy Winckler, Whei Feng, Jennifer M. Marmion, Elisabeth Laine, Heidi E. Greulich, Hsiuyi Tseng, Casey Gates et al. · 2008 · Cancer Research
52. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
    Ana M. Aparicio, Li Shen, Elsa Li Ning Tapia, Jing‐Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Paul Gettys Corn et al. · 2015 · Clinical Cancer Research
53. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
    Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta et al. · 2016 · The Lancet Respiratory Medicine
54. Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
    Vincent A. Miller, Gregory J. Riely, Maureen Frances Zakowski, Allan R. Li, Jyoti D. Patel, Robert T. Heelan, Mark G. Kris, Alan B. Sandler, David Paul Carbone, Anne S. Tsao et al. · 2008 · Journal of Clinical Oncology
55. In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma
    Shahryar E. Mir, Philip C. De Witt Hamer, Przemek M. Krawczyk, Leonora Balaj, An Claes, Johanna M. Niers, Angela A.G. van Tilborg, Aeilko Having Zwinderman, Dirk Geerts, Gertjan J.L. Kaspers et al. · 2010 · Cancer Cell
56. Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
    Victoria M. Rimkunas, Katherine E. Crosby, Daiqiang Li, Yerong Hu, Meghan E. Kelly, Ting‐Lei Gu, Jennifer S. Mack, Matthew R. Silver, Xinmin Zhou, Herbert Haack · 2012 · Clinical Cancer Research
57. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?
    Adi F. Gazdar, Hisayuki Shigematsu, Joachim Herz, John Dorrance Minna · 2004 · Trends in Molecular Medicine
58. Focus on bladder cancer
    Colin P. Dinney, David James McConkey, Randall E. Millikan, Xifeng Wu, Menashe Bar‐Eli, Liana Adam, Ashish M. Kamat, Arlene Odelia Siefker-Radtke, Tomasz Tuziak, Anita Lyn Sabichi et al. · 2004 · Cancer Cell
59. Ruthenium complexes can target determinants of tumour malignancy
    Alberta Bergamo, Gianni Sava · 2007 · Dalton Transactions
60. Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
    Lewis Rowland Roberts, Gregory James Gores · 2005 · Seminars in Liver Disease
61. Molecularly targeted cancer therapy: some lessons from the past decade
    Min Huang, Aijun Shen, Jian Ding, Meiyu Geng · 2013 · Trends in Pharmacological Sciences
62. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
    Y.-L. Wu, D. Planchard, Shun Lü, Hao Sun, N. Yamamoto, Dongwook Kim, Daniel Shao-Weng Tan, James Chih‐Hsin Yang, M. Azrif, Tetsuya Mitsudomi et al. · 2018 · Annals of Oncology
63. Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
    Hui‐Wen Lo, Weiya Xia, Yongkun Wei, Mohamed Ali‐Seyed, Shiu-Feng Kathy Huang, Mien‐Chie Hung · 2005 · Cancer Research
64. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer
    Michael Krypuy, Genni M Newnham, David Morgan Thomas, Matthew Conron, Alexander Dobrovic · 2006 · BMC Cancer
65. Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
    Gregory J. Riely, Mark G. Kris, Binsheng Zhao, Tim J. Akhurst, Daniel T. Milton, Erin Moore, Leslie B. Tyson, William J. Pao, Naiyer A. Rizvi, Lawrence Howard Schwartz et al. · 2007 · Clinical Cancer Research
66. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
    Sun Min Lim, Nicholas L. X. Syn, Byoung Chul Cho, Ross Andrew Soo · 2018 · Cancer Treatment Reviews
67. Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
    Iduna Fichtner, Jana Rolff, Richie Soong, Jens Hoffmann, Stefanie Hammer, Anette Sommer, Michael Becker, Johannes Merk · 2008 · Clinical Cancer Research
68. Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma
    William David Travis, Kavita Garg, Wilbur A. Franklin, Ignacio Ivan Wistuba, Bradley S. Sabloff, Masayuki Noguchi, Ryutaro Kakinuma, Maureen Frances Zakowski, Michelle S. Ginsberg, Robert F. Padera et al. · 2005 · Journal of Clinical Oncology
69. Targeted Therapies for Cancer 2004
    Jeffrey S. Ross, David P. Schenkein, Robert G. Pietrusko, Mark Rolfe, Gerald P. Linette, James Joseph Stec, Nancy E. Stagliano, Geoffrey S. Ginsburg, W. Fraser Symmans, Lajos Pusztai et al. · 2004 · American Journal of Clinical Pathology
70. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Neil Vasan, Pedram Razavi, Jared Lee Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig, Alexander N. Gorelick, Ting-Yu Lin, Eneda Toska et al. · 2019 · Science
71. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent
    Malleshappa N. Noolvi, Harun Patel, Varun Bhardwaj, Ankit Chauhan · 2011 · European Journal of Medicinal Chemistry
72. Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
    Robert Pirker, Felix J.F. Herth, Keith M. Kerr, Martin Filipits, Miquel Tarón, David R. Gandara, Fred R. Hirsch, Dominique H Grunenwald, Helmut Popper, Egbert Frederik Smit et al. · 2010 · Journal of Thoracic Oncology
73. Acquired resistance to tyrosine kinase inhibitors during cancer therapy
    Jeffrey A. Engelman, Jeffrey E. Settleman · 2008 · Current Opinion in Genetics & Development
74. Cancer immunology—analysis of host and tumor factors for personalized medicine
    Shuji Ogino, Jérôme Galon, Charles S. Fuchs, Glenn Dranoff · 2011 · Nature Reviews Clinical Oncology
75. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
    Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Young Hak Kim, Toshiya Katsura et al. · 2012 · Cancer Chemotherapy and Pharmacology
76. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
    Faber, Anthony C., Corcoran, Ryan B., Ebi, Hiromichi, Sequist, Lecia V., Waltman, Belinda A., Chung, Euiheon, Incio, Joao, Digumarthy, Subba R., Pollack, Sarah F., Song, Youngchul et al. · 2011 · Cancer Discovery
77. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas
    Zill, Oliver A., Greene, Claire, Sebisanovic, Dragan, Siew, Lai Mun, Leng, Jim, Vu, Mary, Hendifar, Andrew E., Wang, Zhen, Atreya, Chloe E., Kelley, Robin K. et al. · 2015 · Cancer Discovery
78. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
    Jiannong Li, Uwe Rix, Bin Fang, Yun Bai, Arthur Edwards, Jacques Colinge, Keiryn L. Bennett, Jingchun Gao, Lanxi Song, Steven A. Eschrich et al. · 2010 · Nature Chemical Biology
79. Antitumour immunity regulated by aberrant ERBB family signalling
    Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa · 2021 · Nature reviews. Cancer
80. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
    Heidi E. Greulich, Bethany Kaplan, Philipp Mertins, Tzu-Hsiu Chen, Kumiko Tanaka, Cai‐Hong Yun, Xiaohong Zhang, Se‐Hoon Lee, Jeonghee Cho, Lauren Ambrogio et al. · 2012 · Proceedings of the National Academy of Sciences
81. Pharmacogenomics: Challenges and Opportunities
    Dan M. Roden, Russ Biagio Altman, N L Benowitz, David Alastair Flockhart, Kathleen M. Giacomini, Julie A. Johnson, Ronald M. Krauss, Howard L. McLeod, Mark J. Ratain, Mary V. Relling et al. · 2006 · Annals of Internal Medicine
82. Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes
    Yuan Wan, Gong Cheng, Xin Liu, Si-Jie Hao, Merisa Nisic, Chuan-Dong Zhu, Yi-Qiu Xia, Wen-Qing Li, Zhigang Wang, Wen-Long Zhang et al. · 2017 · Nature Biomedical Engineering
83. Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
    Robert Charles Doebele, Xian Jun David Lu, Christopher Joseph Sumey, DeLee A. Maxson, Andrew James Weickhardt, Ana Belen Oton, Paul A. Bunn, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner et al. · 2012 · Cancer
84. Molecular principles of cancer invasion and metastasis (Review)
    Efferth · 2009 · International Journal of Oncology
85. Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
    Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec, Stefan Curescu, Raimundas Sakalauskas, Georgy Moiseevich Manikhas, Julien Mazières, Renaud Whittom, Carol Ward, Karen Mayne et al. · 2011 · Journal of Clinical Oncology
86. Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
    Amanda J. Redig, Pasi Antero Janne · 2015 · Journal of Clinical Oncology
87. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.
    J. Zuber, Amy R. Rappaport, Weijun Luo, Eric Wang, Chong Chen, Angelina V. Vaseva, Jun-Wei Shi, Susann Weissmueller, Christof Fellmann, Meredith J. Taylor et al. · 2011 · Genes & Development
88. Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
    James M. Bean, Gregory J. Riely, Marissa N. Balak, Jenifer L. Marks, Marc Ladanyi, Vincent A. Miller, William J. Pao · 2008 · Clinical Cancer Research
89. Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
    Hideharu Kimura, Kazuko Sakai, Tokuzo Arao, Tatsu Shimoyama, Tomohide Tamura, Kazuto Nishio · 2007 · Cancer Science
90. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Hajime Asahina, K Yamazaki, Ichiro Kinoshita, Noriaki Sukoh, M. Harada, Hiroshi Yokouchi, Takashi Ishida, Shinji Ogura, T Kojima, Yasushi Okamoto et al. · 2006 · British Journal of Cancer
91. Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
    Kenichi Suda, Kenji Tomizawa, Makiko Fujii, Hideki Murakami, Hirotaka Osada, Yoshihiko Maehara, Yasushi Yatabe, Yoshitaka Sekido, Tetsuya Mitsudomi · 2011 · Journal of Thoracic Oncology
92. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
    Thierry Le Chevalier, Giorgio V. Scagliotti, Ronald B. Natale, Sarah J. Danson, Rafael Rosell, Rolf Arno Stahel, P. A. Thomas, Robin Rudd, Johan Vansteenkiste, N. Thatcher et al. · 2004 · Lung Cancer
93. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
    Alexandre F. Aissa, Abul Bashar Mir Md. Khademul Islam, Majd Ariss, Cammille C. Go, Alexandra E. Rader, Ryan D. Conrardy, Alexa M Gajda, Carlota Rubio-Pérez, Klara Valyi‐Nagy, Mary M. Pasquinelli et al. · 2021 · Nature Communications
94. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
    Fred R. Hirsch, Marileila Varella‐Garcia, Federico Cappuzzo · 2009 · Oncogene
95. Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
    Drilon, Alexander, Wang, Lu, Arcila, Maria E., Balasubramanian, Sohail, Greenbowe, Joel R., Ross, Jeffrey S., Stephens, Phil, Lipson, Doron, Miller, Vincent A., Kris, Mark G. et al. · 2015 · Clinical Cancer Research
96. Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma
    Ken Wyman, Michael B. Atkins, Victor Prieto, Omar E. Eton, David F. McDermott, Francie J. Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey Alan Sosman · 2006 · Cancer
97. Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
    Colin C. Pritchard, Stephen J. Salipante, Karen M. Koehler, Christina Smith, Sheena M. Scroggins, Brent Lee Wood, David Wu, Ming K. Lee, Suzanne M. Dintzis, Andrew Adey et al. · 2013 · Journal of Molecular Diagnostics
98. l ‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth
    Koji Oda, Noriko Hosoda, Hiroshi Endô, Kunio SAITO, Kenji Tsujihara, Michio Yamamura, Takeshi Sakata, Naohiko Anzai, Michael F. Wempe, Yoshikatsu Kanai et al. · 2009 · Cancer Science
99. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
    Toni Michel Brand, Mari Iida, Deric L. Wheeler · 2011 · Cancer Biology & Therapy
100. Diagnosis and Molecular Classification of Lung Cancer
     Jaime Rodriguez‐Canales, Edwin Roger Parra-Cuentas, Ignacio Ivan Wistuba · 2016 · Cancer treatment and research